An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Tavokinogene telsaplasmid (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 14 Mar 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 14 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 14 Mar 2017 Status changed from active, no longer recruiting to recruiting.